Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

Top 10 Oil-producing Countries (Updated 2024)

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Can You Invest in Elon Musk’s Neuralink? (Updated 2024)

Top 10 Countries for Natural Gas Production (Updated 2024)

Top 10 Copper-producing Companies (Updated 2024)

Investing in Graphene Companies (Updated 2024)

7 Biggest Lithium-mining Companies in 2024

Hydrogen Stocks: 9 Biggest Companies in 2024

Trending Press Releases

Falco Announces Creation of Technical and Strategic Committees With Glencore Canada Corporation

Element79 Announces Uplisting to OTCQB Venture Market

Sale of JWD Iron Ore Mining Rights

RAD Increases Ownership in Radiopharm Ventures to 75%

Lode Gold Signs $3.5 Million Strategic Alliance; Creating One of the Largest Prospective Land Packages in New Brunswick

Offtake Prepayment MOU

More Press Releases
Trending Companies

Galan Lithium

GLN:AU

Anax Metals Limited

ANX:AU

Black Swan Graphene

SWAN:CC

Soma Gold Corp.

SOMA:CA
More Companies
Trending Reports

2024 AI Market Outlook Report

2024 Gold Outlook Report

2024 Oil & Gas Outlook Report

2024 Lithium Market Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Cynata Therapeutics

ASX:CYP

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus.

Press Releases

Cynata’s Cymerus MSCs Ameliorate Cytokine Release Syndrome in Preclinical Study

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Interactive Chart

×